Related Experiment Video
Updated: Jan 26, 2026

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
Advancing pharmacotherapy for diabetic foot ulcers
Ioanna Eleftheriadou1, Anastasios Tentolouris1, Nikolaos Tentolouris1
1a Diabetes Centre, First Department of Propaedeutic Internal Medicine , Medical School, National and Kapodistrian University of Athens, Laiko General Hospital , Athens , Greece.
Newer treatments for diabetic foot ulcers (DFUs) show promise. Advanced options like empagliflozin, liraglutide, and platelet-rich plasma (PRP) may improve outcomes for non-healing DFUs.
Area of Science:
- Diabetology
- Wound Healing
- Pharmacology
Background:
- Standard diabetic foot ulcer (DFU) treatments often yield unsatisfactory outcomes.
- Effective management requires addressing off-loading, debridement, infection, peripheral arterial disease (PAD), and glycemic control.
Purpose of the Study:
- To outline novel pharmacological agents for DFU management.
- To provide expert perspectives on future DFU treatment strategies.
Main Methods:
- Review of current literature on DFU management.
- Expert opinion on emerging therapies and future research directions.
Main Results:
- Empagliflozin and liraglutide are recommended for glycemic control in DFUs with PAD.
- Evolocumab may benefit DFUs with unmet cholesterol goals.
- Sucrose octasulfate dressings, becaplermin gel, and platelet-rich plasma (PRP) are potential advanced treatments.
Conclusions:
- High-quality evidence from RCTs is needed for new DFU guidelines.
- Further studies are warranted to develop treatment algorithms for refractory DFUs.
- Emerging therapies offer new hope for managing complex diabetic foot ulcers.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Psychosis: Goals of Pharmacotherapy
Muscles of the Leg that Move the Foot and Toes
Anterior Compartment
The anterior compartment includes muscles that contribute to the dorsiflexion of the foot. This compartment houses the tibialis anterior, extensor hallucis longus, and extensor digitorum longus muscles....
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

